Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon May 13, 2021 10:11am
138 Views
Post# 33190915

RE:RE:What kind of imbecile sells at a loss when biz is booming?

RE:RE:What kind of imbecile sells at a loss when biz is booming?Would of, should of, could of - hindsight is such a wonderful thing!

Reality check here is that very very few sold this in the $1.50's - after all, there it was at $ 1.57 with two guaranteed NRs - one assured to announce huge revs and the other a roll out of the company's long awaited (18 years) novel product to change the world.  Anyone in their right mind believed this was going to $3-4 after the releases so hitting the sell button was a hard thing to do.  What actually happended next is now old and sad history.

Will this stay in the $.60s - I think not because today this is a money making company now and something has to break on Aristotle - maybe not next month but when it does and we actually catch a break here, all of this ugliness could be forgotten.  Then again, maybe no one wants or is willing to pay for cancer detection services and this falls flat, covid dries up and we go to $.20 cents - really its a matter of what you believe.


InvrsContrarian wrote: Binder dundat. Always next quarter. I stayed for cancer and got burned. I should have sold at 1.50 and 0.10 for all my. Wt warrants. But I drank too much of the kool aid. But what do I know, I'm a relatively new investor.and this stock learned me alot. That is too take profit off the table when the timeis right and the stock is at its all times highs. Like 3 times right before the quarterly reports. I was a fool to not take that money. Mistake made and never again to be taken to the cleaners. But I made it out with my original investment. But 0%gain for 10 months of investment cost me many multiples on other plays. Good. Luck maybe jt will pull a. Good cc who knows but the odds are not in his favour.
gojotv! wrote: I swear some of these morons must be allergic to money!
Great quarterly report - expanding partnerships - first to market, breakthrough medical technology - expanded Covid testing - rosy short and long-term outlooks...
This stock should be well over a dollar by now, and inching up on its price target of $1.25.
To sell is to lose your stake.
Buh-bye, losers.




<< Previous
Bullboard Posts
Next >>